New Orleans Sun
NewOrleansSun.com Tuesday 9th March 2010 Issue 2148
  • More Breaking Health News

  • New research may expand drug arsenal used to fight HIV
  • Online questionnaire effective screening tool for mental health problems
  • Brit woman gives birth - just 3hrs after finding she was pregnant!
  • Palin in hot water over revelations of medical treatment in Canada
  • 'Smart' nanoparticles target specific cancer cells
  • New asthma program to specifically help teens
  • Placido Domingo undergoes colon cancer surgery
  • Britain to donate 42m condoms to South Africa prior to Soccer WC
  • Ryder racing toward fitness ahead of World T20 championship
  • Nicotine rises "gradually" in the brain
  • Anti-depressants linked to higher risk of cataracts
  • Prostate cancer patients should not take dietary supplements
    Get Breaking Health News headlines emailed to you daily.

    Popular anti-depressant interferes with breast cancer treatment
    New Orleans Sun
    Tuesday 9th February, 2010  
    (ANI)


    London, Feb 9 : Taking a popular anti-depressant could slash chances of survival for women battling breast cancer, says a new study.

    Seroxat can interfere with a key breast cancer drug, say experts.

    Women taking tamoxifen to fight breast tumours were less likely to survive if they also took the antidepressant, reports The Daily Express.

    The researchers said the results had "major implications for clinical practice" and warned women on Seroxat to see their GP.

    In the British Medical Journal study, researchers from the University of Toronto looked at 2,430 women aged over 66 who were taking tamoxifen and one of five anti-depressants. Those taking Seroxat were more likely to die from breast cancer and were slightly more likely to die from any other cause compared with women not on Seroxat.

    The authors said: "Our findings indicate that the choice of anti
    ­depressant can significantly affect survival in women receiving tamoxifen for breast cancer."

      Email this story to a friend

    Have your say on this story

    Your nickname (optional)
    Message